ArticleTherapeutic advances in medical oncology2026

Cadonilimab plus chemotherapy for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in China and the United States: a cost-effectiveness analysis.

Jia Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.